Stay updated on Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated to version 2.15.0, replacing the previous version 2.14.4.SummaryDifference1.0%
- Check13 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check56 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check70 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check78 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check92 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
Stay in the know with updates to Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.